Mechanism for IL-1β-mediated neovascularization unmasked by IL-1β knock-out mice

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 4, 2004, Pages 469-480

  Amano, Katsuya ^a   Okigaki, Mitsuhiko ^a   Adachi, Yasushi ^a   Fujiyama, Soichiro ^a   Mori, Yasukio ^a   Kosaki, Atsushi ^a   Iwasaka, Toshiji ^a   Matsubara, Hiroaki ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; HIF 1 ; IL 1 ; Ischemia; Neovascularization; VEGF

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CAPILLARY; CELL ACTIVITY; CELL COUNT; CELL DIFFERENTIATION; CELL POPULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL MOUSE; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; KNOCKOUT MOUSE; LEG MUSCLE; LIMB ISCHEMIA; MALE; MOLECULAR DYNAMICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION; WILD TYPE;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD31; ANTIGENS, CD34; ANTIGENS, CD45; BLOTTING, WESTERN; CALIBRATION; CELL DIFFERENTIATION; CELL SEPARATION; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; ISCHEMIA; KI-67 ANTIGEN; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 1842765614     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.01.006     Document Type: Article

References (39)

1. Risau W., Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol. 11:1995;73-91.
2. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., et al. Expression of VEGF-2 and AC133 by circulating human CD34+ cells identified a population of functional endothelial precursors. Blood. 95:2000;952-958.
3. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:1999;3964-3972.
4. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
5. Shalaby F., Rossant J., Yamaguchi T., Gertsenstein M., Wu X.F., Breitman M.L., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
6. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
7. Whitaker G.B., Limberg B.J., Rosenbaum J.S. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem. 276:2001;25520-25531.
8. Takashima S., Kitakaze M., Asakura M., Asanuma H., Sanada S., Tashiro F., et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA. 99:2002;3657-3662.
9. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1996;1171-1180.
10. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:1997;55-60.
11. Maruyama K., Mori Y., Murasawa S., Masaki H., Takahashi N., Tsutusmi Y., et al. Interleukin-1 beta upregulates cardiac expression of vascular endothelial growth factor and its receptor KDR/flk-1 via activation of protein tyrosine kinases. J Mol Cell Cardiol. 31:1997;607-617.
12. Aoki Y., Jaffe E.S., Chang Y., Jones K., Teruya-Feldstein J., Moore P.S., et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 93:1999;4034-4043.
13. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 258:1992;1798-1801.
14. Park C.C., Morel J.C., Amin M.A., Connors M.A., Harlow L.A., Koch A.E. Evidence of IL-18 as a novel angiogenic mediator. J Immunol. 167:2000;1644-1653.
15. Leibovich S.J., Polverini P.J., Shepard H.M., Wiseman D.M., Shively V., Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrotic factor-α Nature. 329:1987;630-632.
16. Hu D.E., Hori Y., Presta M., Gresham G.A., Fan T.P. Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation. 18:1994;45-58.
17. Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., Maemondo M., et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol. 169:2002;469-475.
18. Salven P., Hattori K., Heissig B., Rafii S. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. 16:2002;1471-1473.
19. Berse B., Hunt J.A., Diegel R.J., Morganelli P., Yeo K., Brown F., et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol. 115:1999;176-182.
20. Jung Y.D., Liu W., Reinmuth N., Ahmad S.A., Fan F., Gallick G.E., et al. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis. 4:2001;155-162.
21. Horai R., Asano M., Sudo K., Kanuka H., Suzuki M., Nishihara M., et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med. 187:1998;1463-1475.
22. Okabe M., Ikawa M., Kominami K., Nakanishi T., Nishimine Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 407:1997;313-319.
23. Kabrun N., Buhring H.J., Choi K., Ullrich A., Risau W., Keller G. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development. 124:1997;2039-2048.
24. Basu A., Krady J.K., O'Malley M., Styren S.D., DeKosky S.T., Levison S.W. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci. 22:2002;6071-6082.
25. Ruegg C., Postigo A.A., Sikorski E.E., Butcher E.C., Pytela R., Erle D.J. Role of integrin alpha 4 beta 7/alpha 4 beta P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol. 117:1992;179-189.
26. Kwee L., Baldwin H.S., Shen H.M., Stewart C.L., Buck C., Buck C.A., et al. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development. 121:1995;489-503.
27. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 100:2003;2645-2650.
28. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest. 99:1997;373-376.
29. Hanmaaijer R., Koolwik P., leClercq L., de Vree W.J., van Hinsbergh V.W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects tumor necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J. 296:1993;803-809.
30. Giulian D., Woodward J., Young D.G., Krebs J.F., Lachman L.B. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci. 8:1988;2485-2490.
31. Mizushima H., Zhou C.J., Dohi K., Horai R., Asano M., Iwakura Y., et al. Reduced postischemic apoptosis in the hippocampus of mice deficient in interleukin-1. J Comp Neurol. 448:2002;203-216.
32. Touzani O., Boutin H., LeFeuvre R., Parker L., Miller A., Luheshi G., et al. Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J Neurosci. 22:2002;38-43.
33. 2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
34. 2 sensing. Science. 292:2001;464-468.
35. Cao M., Westerhausen-Larson A., Niyibizi C., Kavalkovich K., Georgescu H.I., Rizzo C.F., et al. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J. 324:1997;305-310.
36. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell. 21:2001;3995-4004.
37. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 277:2002;27975-27981.
38. Gao N., Ding M., Zheng J.Z., Zhang Z., Leonard S.S., Liu K.J., et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem. 277:2002;31963-31971.
39. Funakoshi M., Sonoda Y., Tago K., Tominaga S., Kasahara T. Differential involvement of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase in the IL-1-mediated NF-kappa B and AP-1 activation. Int Immunopharmacol. 1:2001;595-604.